The JAK2V617F mutation and thrombosis
Open Access
- 14 October 2008
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 143 (3), 307-320
- https://doi.org/10.1111/j.1365-2141.2008.07258.x
Abstract
Since the discovery of the JAK2V617F mutation, the clinical and pathological consequences of this acquired defect have been extensively investigated to determine whether its presence characterises a distinct subgroup of myeloproliferative disorders (MPD). MPD management remains highly dependent on the patient’s thrombotic risk. Whether the presence of the JAK2V617F mutation modifies the thrombotic risk is currently contentious, although there is increasing clinical evidence to suggest that the mutation may be variably associated with thrombosis. These observations are further supported by laboratory parameters which suggest that the JAK2V617F mutation may confer increased activation of leucocytes and platelets in MPD. The role of screening for the JAK2V617F mutation in patients presenting with thrombosis without overt MPD is unclear, but appears justified in cases of idiopathic splanchnic vein thrombosis.Keywords
This publication has 89 references indexed in Scilit:
- The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 casesBlood, 2008
- Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolismJournal of Thrombosis and Haemostasis, 2008
- Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settingsJournal of Medical Genetics, 2007
- JAK2V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disordersLeukemia, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisNew England Journal of Medicine, 2007
- The haematocrit and platelet target in polycythemia veraBritish Journal of Haematology, 2006
- JAK2V617F: prevalence in a large Chinese hospital populationBlood, 2006
- Hydroxyurea Compared with Anagrelide in High-Risk Essential ThrombocythemiaNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disordersAnnals of Hematology, 1991